COMMUNIQUÉS West-GlobeNewswire

Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
23/02/2026
Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS ), a clinical- [...]
Coherus Oncology to Participate in Upcoming Investor Conferences
23/02/2026
REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible [...]
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
23/02/2026
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Boca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” [...]
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
23/02/2026
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a [...]
SafeSpace Global Corporation Transitions from Pre-Revenue to Active Revenue Generation with Eight Contracted Senior Living Facility Installations
23/02/2026
Company Begins Recurring Monthly Revenue Stream in February 2026 through Deployment of AI-powered, Privacy-Aware Technology that Replaces Wearables and Loud Alarms with Proactive and Dignified Resident Safety KNOXVILLE [...]
Nucleus Upgrades Preview, The First True Glimpse of Your Future Child
23/02/2026
Couples can now model 100 potential children across rare and common diseases, offering the most complete picture of inheritance yet. NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Nucleus Genomics today introduced Preview [...]
Editas Medicine to Participate in Upcoming Investor Conferences
23/02/2026
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that [...]
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
23/02/2026
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making [...]
Neutrolis Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors as Executive Director
23/02/2026
Dr. Dolsten, former Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer, brings leadership experience spanning approximately 50 regulatory approvals and over $100 billion in [...]
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
23/02/2026
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
23/02/2026
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care [...]
Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
23/02/2026
MINNEAPOLIS and BRISBANE, Australia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
TOMI Environmental Solutions Receives Biocidal Product Approvals in Great Britain and Northern Ireland
23/02/2026
Health and Safety Executive (HSE) grants Authorization Nos.: GB-2016-1042 and NI-2026-1350 FREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader [...]
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved
23/02/2026
CagriSema achieved 23% weight loss after 84 weeks of treatment CagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks 1 Additional [...]
RE+Vitalize Health and Nutrition Announces Initiative to Advance Clean and Transparent Supplement Standards
23/02/2026
Elizabeth City, NC, Feb. 23, 2026 (GLOBE NEWSWIRE) -- RE+Vitalize Health and Nutrition, a retail health and nutrition brand based in Elizabeth City, announced an initiative focused on advancing clean and transparent [...]
Pulselight platform now available to NHS via £10bn Fortrus Framework
23/02/2026
Pulselight’s platform can now be procured for NHS organisations via this pre-approved route to market LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pulselight, a leading healthcare data analytics provider, is now an [...]
Opterion Health AG Announces First Patient enrolled in Phase 1 SPARC Trial Following CTA Approval for OPT101
23/02/2026
MUTTENZ, Switzerland, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Opterion Health AG today announced that the first patient has been successfully enrolled in its Phase 1 SPARC trial. This marks the official start of the company’s [...]
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
23/02/2026
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be [...]
argenx to Present at TD Cowen 46th Annual Healthcare Conference
23/02/2026
February 23, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]

Pages